Enterprise Value

6.868M

Cash

44.43M

Avg Qtr Burn

-20.71M

Short % of Float

3.33%

Insider Ownership

11.80%

Institutional Own.

43.86%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Zokinvy™ (lonafarnib) Details
Progeroid laminopathies, Progeria, Hutchinson-Gilford progeria syndrome

Approved

Quarterly sales

Avexitide (GLP-1 Antagonist) Details
Metabolic disorder, Congenital Hyperinsulinism

Phase 3

Update

Lonafarnib Details
Liver disease, Infectious disease, Hepatitis D

Phase 3

Update

Avexitide (GLP-1 Antagonist) Details
Metabolic disorder, Post-Bariatric Hypoglycemia, Rare diseases

Phase 3

Update

Peginterferon Lambda + Lonafarnib Details
Infectious disease, Hepatitis D

Phase 2

Update

Failed

Discontinued

Peginterferon Lambda (Lambda) Details
Infectious disease, Hepatitis D

Failed

Discontinued